PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Primary Endocrine Therapy vs Surgery in Older ER-Positive Breast Cancer: Biology Defines Candidates

primary endocrine therapytamoxifenaromatase inhibitorsestrogen receptor-positive breast cancerolder adultsgeriatric oncologysurgery omissionsystematic reviewmeta-analysiscompeting mortalityctDNA Oncology Pharmacy

Background Information

No survival difference found between endocrine therapy and surgery in older breast cancer patients.

Identifying appropriate treatment strategies for older women with estrogen receptor-positive breast cancer is crucial for optimizing outcomes. Primary endocrine therapy (pET) and surgery showed no significant difference in overall survival for these patients (HR, 1.14; 95% CI, 0.98-1.33). Study suggests considering tumor biology and frailty, rather than age alone, to determine candidacy for pET. Limitations include heterogeneity across trials. Consider tumor biology and frailty, not just age, for pET candidacy.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Carleton N, Zou J, Mu Y, Oesterreich S, Puhalla S, Foldi J, Tseng G, Lee AV, McAuliffe PF

Citation: Carleton N, Zou J, Mu Y, et al. Primary Endocrine Therapy vs Upfront Surgery for Older Women With Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-Analysis. JAMA network open. 2026;9(11):e2643218. doi:10.1001/jamanetworkopen.2026.43218

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.